Regulatory approvals for treatment-resistant depression (TRD) are limited to a small number of specific treatments, including transcranial magnetic stimulation (such as the Stanford Accelerated Intelligent Neuromodulation Therapy), the combination of olanzapine and fluoxetine, and intranasal esketamine.

Authors

• Person: Not available Organization: Frontiers in Psychiatry
  The Montreal model: an integrative biomedical-psychedelic ...

Sources

• The Montreal model: an integrative biomedical-psychedelic ... www.frontiersin.org Frontiers in Psychiatry via serper

Referenced by nodes (3)

• treatment-resistant depression concept
• esketamine concept
• transcranial magnetic stimulation concept